FDA/EMEA To Hold Joint Pharmacogenomic Meetings
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and the European Medicines Agency will offer voluntary genomic data submission sponsors the option of joint FDA/EMEA briefing meetings, the agencies said May 31
You may also be interested in...
Pharmacogenomics' Next Step: Public Workshop In April
After releasing a final guidance for industry data submissions, FDA continues to seek input on additional pharmacogenomic guidances. The agency will release a concept paper on co-development of drugs and diagnostics for the April 11-13 workshop.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.